Improved Platelet Availability with Pathogen Reduction
Today, pathogen reduction (PR) provides the potential to release platelet products for transfusion sooner after collection; delayed platelet release into inventory inherent with culture-based methods is not necessary.1
Cerus continues to make progress on its two-stage recovery and survival study to support its FDA submission for 7-day storage of INTERCEPT processed platelets. A submission for platelets in 100% plasma and in 35% plasma/65% PAS is targeted by 2021. (ClinicalTrials.gov Identifier: NCT04022889)
Additional Resources
Cerus Webinar Replay: Patient Safety and FDA Platelet Bacterial Guidance Compliance with Dr. Richard Benjamin (Cerus Corporation)
Cerus Webinar Replay: A Software Model to Estimate the Cost and Shelf Life Implications of New Platelet Technologies with Dr. Laura Pizzi (Rutgers University)
Podcast: Preparing our Blood Supply for the Nest Pandemic with Dr. Susan Stramer (American Red Cross)
You May Also Be Interested In
There is no pathogen inactivation process that has been shown to eliminate all pathogens. Refer to the package insert for more information.
1. Bacterial Risk Control Strategies for Blood Collection Establishments and Transfusion Services to Enhance the Safety and Availability of Platelets for Transfusion: Draft Guidance for Industry, December 2020.